



IRRAS EXPANDS ITS MANAGEMENT GROUP

Stockholm, Sweden, October 19, 2018 – IRRAS AB (Nasdaq First North Premier: IRRAS) announced today that, as of October 19, the IRRAS management consists of the following groups and persons:

Executive Management Team

Kleanthis G. Xanthopoulos, Ph.D.	President & CEO
Fredrik Alpsten	CFO and Deputy CEO
Will Martin	Chief Commercial Officer
Lance Boling	Vice President, Product Development
Kellie Fontes	Senior Director, Human Capital

Extended Management Group

Adam Sampson	Vice President, Product Excellence
Dino De Cicco	Senior Director, Product Development
Dessi Lyakov	Director, Regulatory & Quality
Sabina Berlin	Vice President, Finance

Simultaneously with the above mentioned management changes, Karl-Matthias Moehlmann, Senior Vice President, Commercial Operations and General Manager, Europe, has left IRRAS.

For more information, please contact:

US

Kleanthis G. Xanthopoulos, Ph.D.
President & CEO

info@irras.com

Europe

Fredrik Alpsten
CFO and Deputy CEO

+46 706 67 31 06

fredrik.alpsten@irras.com

About IRRAS

IRRAS AB (Nasdaq First North Premier: IRRAS) is a publicly-traded, commercial-stage medical technology company focused on developing and commercializing innovative solutions for brain surgery. The company's initial product, IRRAS*flow*[®], addresses the

complications associated with the current methods of managing intracranial fluid by using a dual lumen catheter that combines active irrigation with ongoing fluid drainage. *IRRAflow* received FDA clearance in July 2018.

Regularly during treatment, the *IRRAflow* catheter is automatically flushed to prevent common catheter occlusions from forming. Because *IRRAflow* is a completely closed system, it is designed to reduce the documented infection risk of these procedures. Additionally, *IRRAflow* incorporates ICP monitoring and uses a proprietary software to regulate treatment based on desired pressure levels.

With its unique product portfolio, protected by property patents and patent applications, IRRAS is well positioned to establish a leadership position in the medical device market. IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.rras.com

IRRAS AB (publ) is listed on Nasdaq First North Premier. Wildeco is certified adviser of the company.

This document is considered information that IRRAS is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person above, on October 19, 2018 at 8.00 a.m. (CET).